방사선종양학

본문글자크기
  • [Radiat Oncol J .] Clinical utilization of radiation therapy in Korea between 2017 and 2019

    2023년 03월호
    [Radiat Oncol J .] Clinical utilization of radiation therapy in Korea between 2017 and 2019

    KIRAMS / 김은지, 장원일*

  • 출처
    Radiat Oncol J .
  • 등재일
    2022 Dec
  • 저널이슈번호
    40(4):251-259. doi: 10.3857/roj.2022.00500. Epub 2022 Dec 27.
  • 내용

    바로가기  >

    관련논문보기

     

    Abstract
    Purpose: This study aimed to evaluate the clinical infrastructure and utilization of radiotherapy (RT) services in Korea between 2017 and 2019.

    Materials and methods: We extracted the data of patients who underwent RT between 2017 and 2019 from the Health Insurance Review and Assessment Service. We further analyzed this data according to the diagnosis and treatment modalities of patients diagnosed with International Classification of Disease 10 (ICD-10) diagnostic codes C00-C97 and D00-D48. In addition, we collected statistics on RT facilities in Korea using a nationwide survey.

    Results: The total number of patients who received RT in 2017, 2018, and 2019 were 77,901, 81,849, and 87,460, respectively. The number of patients diagnosed with ICD 10 C- and D-codes in 2019 was 86,339, of whom 39,467 were men and 46,872 women. The rate of utilization of RT among cancer patients was 30.4% in 2017 and 2018 and 30.9% in 2019. In 2019, the most common types of cancers treated with RT were breast, lung, prostate, colorectal, and liver cancers. Regarding the RT infrastructure in Korea, there were 95 radiation oncology centers, 237 megavoltage (MV) teletherapy units, 35 brachytherapy units, and two proton accelerators in 2019. There were 4.5 MV teletherapy machines per million.

    Conclusion: The number of patients treated with RT has increased consistently from 2017 to 2019. As the number of patients with cancer increases, it is expected that the RT infrastructure will be further expanded in Korea.

     

     

     

     

    Affiliations

    Eunji Kim 1, Won Il Jang 1, Kwangmo Yang 1, Mi-Sook Kim 1, Hyung Jun Yoo 1, Eun Kyung Paik 1, Heejin Kim 2, Jaesun Yoon 3
    1Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
    2External Strategy Team, Strategic Planning Office, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
    3Department of Biostatistics, Korea University, Seoul, Korea.

  • 키워드
    Korea; Neoplasms; Radiotherapy; Statistics.
  • 연구소개
    건강보험심사평가원의 빅테이터를를 분석하여 우리나라의 2017년부터 2019년까지 방사선치료의 임상적 활용 현황과 방사선치료 인프라를 분석한 논문입니다. 방사선치료를 받는 환자수 및 인프라는 지속적으로 증가하고 있음을 보여주고 있습니다. 2017년부터 전체 암환자의 30% 이상이 방사선치료를 받았으며, 2018년부터 방사선치료를 받는 환자수가 8만명을 넘었으며, 2019년부터 전립선암이 우리나라에서 3번째로 방사선치료를 많이 받는 암종으로 나타났습니다. 방사선치료의 임상적 수요 증가와 함께 관련 인프라도 더욱 강화되야 하는 근거를 제공해 주는 연구로 생각합니다.
  • 편집위원

    국내 방사선치료의 현황을 분석한 논문으로 대한방사선종양학회 정보위원회 명의의 공식 통계논문임

    덧글달기2023-03-07 08:56:18

  • 편집위원2

    2017년부터 2019년까지 3년간 방사선 치료 현황에 대해 분석한 논문으로서 지속적으로 향우 방사선치료분야의 발전 방향 등에 대해 이해할 수 있도록 도움을 줄 수 있는 논문

    덧글달기2023-03-07 09:28:15

  • 덧글달기
    덧글달기
       IP : 3.236.143.154

    등록